Ask AI
ProCE Banner Series

Emerging Clinical Data and Evolving Management Strategies in Lower-Risk MDS With Anemia

This program will explore recently emerging clinical data for an oligonucleotide telomerase inhibitor for the management of transfusion-dependent anemia in patients with LR-MDS. The discussion will review key efficacy and safety findings, examine clinically meaningful outcomes such as transfusion independence and durability of response, and consider how these data may shape the evolving treatment paradigm.

Key Takeaways

  • Review the current management approach for anemia in patients with lower-risk MDS and the evolving therapeutic landscape.
  • Examine recent clinical data for an oligonucleotide telomerase inhibitor and their implications for clinical decision-making.
  • Discuss practical considerations for applying current evidence and emerging treatment strategies in appropriate patients with lower-risk MDS.

All Events

Emerging Clinical Data and Evolving Management Strategies in Lower-Risk MDS With Anemia

Upcoming Events

August

27

2026

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual